Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Conforti

Showing results (11-20 of 20) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 20 results.
Giornale Italiano Di Oncologia|July 1, 1990
[Ascites and carcinoma of the endometrium]C Di Serio, S Conforti, D Cirillo, et al.
European Journal of Cancer (Oxford, England : 1990)|January 1, 1994
Carboplatin and alpha-2b interferon intraperitoneal combination as first-line treatment of minimal residual ovarian cancer. A pilot studyG Frasci, A Tortoriello, G Facchini, et al.
Gynecologic Oncology|July 1, 1993
Intraperitoneal (ip) cisplatin-mitoxantrone-interferon-alpha 2b in ovarian cancer patients with minimal residual diseaseG Frasci, A Tortoriello, G Facchini, et al.
Minerva Chirurgica|January 11, 2007
Diagnostic value and learning curve of transbronchial needle aspiration in thoracic surgeryF Raveglia, S Meda, S Conforti, et al.
Cancer|March 15, 1996
A risk model for ovarian carcinoma patients using CA 125: time to normalization renders second-look laparotomy redundantG Frasci, S Conforti, F Zullo, et al.
Human Mutation|February 12, 2000
Hereditary nonpolyposis coloretal cancer: identification of novel germline mutations in two kindreds not fulfulling the Amsterdam criteria. Mutations in brief no. 203. OnlineB Quaresima, C Grandinetti, F Baudi, et al.
Clinical Endocrinology|April 24, 2004
Effects of recombinant LH (rLH) supplementation during controlled ovarian hyperstimulation (COH) in normogonadotrophic women with an initial inadequate response to recombinant FSH (rFSH) after pituitary downregulationG De Placido, C Alviggi, A Mollo, et al.
Human Mutation|July 20, 2001
Evidence of a founder mutation of BRCA1 in a highly homogeneous population from southern Italy with breast/ovarian cancerF Baudi, B Quaresima, C Grandinetti, et al.
European Journal of Cancer (Oxford, England : 1990)|November 1, 2002
Rationale for a study adding tamoxifen to HRTN Rotmensz, A Decensi, P Maisonneuve, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|May 7, 2025
Real-life effectiveness and safety of tofacitinib and vedolizumab as 2nd-line for ulcerative colitis after anti-TNFs: A multicenter cohort IGIBD study (VE2TO-UC)D Noviello, W Fries, A Orlando, et al.
Pageof 2

Showing results (11-20 of 20) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 20 results.
Giornale Italiano Di Oncologia|July 1, 1990
[Ascites and carcinoma of the endometrium]C Di Serio, S Conforti, D Cirillo, et al.
European Journal of Cancer (Oxford, England : 1990)|January 1, 1994
Carboplatin and alpha-2b interferon intraperitoneal combination as first-line treatment of minimal residual ovarian cancer. A pilot studyG Frasci, A Tortoriello, G Facchini, et al.
Gynecologic Oncology|July 1, 1993
Intraperitoneal (ip) cisplatin-mitoxantrone-interferon-alpha 2b in ovarian cancer patients with minimal residual diseaseG Frasci, A Tortoriello, G Facchini, et al.
Minerva Chirurgica|January 11, 2007
Diagnostic value and learning curve of transbronchial needle aspiration in thoracic surgeryF Raveglia, S Meda, S Conforti, et al.
Cancer|March 15, 1996
A risk model for ovarian carcinoma patients using CA 125: time to normalization renders second-look laparotomy redundantG Frasci, S Conforti, F Zullo, et al.
Human Mutation|February 12, 2000
Hereditary nonpolyposis coloretal cancer: identification of novel germline mutations in two kindreds not fulfulling the Amsterdam criteria. Mutations in brief no. 203. OnlineB Quaresima, C Grandinetti, F Baudi, et al.
Clinical Endocrinology|April 24, 2004
Effects of recombinant LH (rLH) supplementation during controlled ovarian hyperstimulation (COH) in normogonadotrophic women with an initial inadequate response to recombinant FSH (rFSH) after pituitary downregulationG De Placido, C Alviggi, A Mollo, et al.
Human Mutation|July 20, 2001
Evidence of a founder mutation of BRCA1 in a highly homogeneous population from southern Italy with breast/ovarian cancerF Baudi, B Quaresima, C Grandinetti, et al.
European Journal of Cancer (Oxford, England : 1990)|November 1, 2002
Rationale for a study adding tamoxifen to HRTN Rotmensz, A Decensi, P Maisonneuve, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|May 7, 2025
Real-life effectiveness and safety of tofacitinib and vedolizumab as 2nd-line for ulcerative colitis after anti-TNFs: A multicenter cohort IGIBD study (VE2TO-UC)D Noviello, W Fries, A Orlando, et al.
Pageof 2